UFT E combination granule T200 [Folinate combination therapy] (ユーエフティE配合顆粒T200［ホリナート併用療法］)

Land: Japan

Språk: engelsk

Kilde: すりの適正使用協議会 RAD-AR Council, Japan

Aktiv ingrediens:

Tegafur; Uracil

Tilgjengelig fra:

TAIHO Pharmaceutical Co.,LTD.

INN (International Name):

Tegafur; Uracil

Legemiddelform:

white to yellowish white granules

Produkt oppsummering:

Print on wrapping: ユーエフティE配合顆粒T200 200 mg/1 g,TC439

Informasjon til brukeren

Drug Information Sheet("Kusuri-no-Shiori")
Internal
Published: 09/2009
The information on this sheet is based on approvals granted by the
Japanese regulatory authority. Approval
details may vary by country. Medicines have adverse reactions (risks)
as well as efficacies (benefits). It is
important to minimize adverse reactions and maximize efficacy. To
obtain a better therapeutic response,
patients should understand their medication and cooperate with the
treatment.
BRAND NAME:
UFT E COMBINATION GRANULE T200 [FOLINATE
COMBINATION THERAPY]
ACTIVE INGREDIENT:
Tegafur
Uracil
DOSAGE FORM:
white to yellowish white granules
IMPRINT OR PRINT ON WRAPPING:
ユーエフティ E 配合顆粒 T200 200 mg/1 g,TC439
EFFECTS OF THIS MEDICINE
This medicine enhances antitumor effects by combining tegafur and
uracil. Tegafur is
converted into fluorouracil, which attacks cancer cells, and uracil
suppresses the degradation
of fluorouracil. This therapy is expected to relieve symptoms through
reduction in the size of
cancer (tumor).
It enhances the antitumor effects of the anti-cancer medicine when
used concomitantly with
this medicine and a uzel (folinate).
It is usually used to treat colorectal cancer.
THE FOLLOWING PATIENTS MAY NEED TO BE CAREFUL WHEN USING THIS
MEDICINE.BE SURE TO TELL YOUR DOCTOR
AND PHARMACIST.
・If you have previously experienced any allergic reactions (itch,
rash, etc.) to any medicines
or foods.
If you have bone marrow suppression (decrease in white blood cell
count, etc.), diarrhea,
infections, renal disorder, gastrointestinal ulcer/bleeding, diabetes
mellitus or varicella
(chickenpox).
If you have or have a history of liver disorder or heart disease.
If you are currently receiving radiotherapy.
If you have been treated with anti-cancer medicines before.
If you are taking TS-1 (a fluoropyrimidine) or have taken this
combined medicine within the
last 7 days.
・If you are pregnant or breastfeeding.
・If you are taking any other medicinal products. (Some medicines may
interact to enhance or
diminish medicina